Frequent down regulation of the tumor suppressor gene a20 in multiple myeloma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25856582.
- Also identified by DOI 10.1371/journal.pone.0123922 and PMC identifier 4391781.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Multiple myeloma (MM) is a malignant clonal expansion of plasma cells in the bone marrow and belongs to the mature B-cell neoplams. The pathogenesis of MM is associated with constitutive NF-κB activation. However, genetic alterations causing constitutive NF-κB activation are still incompletely understood. Since A20 (TNFAIP3) is a suppressor of the NF-κB pathway and is frequently inactivated in various lymphoid malignancies, we investigated the genetic and epigenetic properties of A20 in MM. In total, of 46 patient specimens analyzed, 3 single base pair exchanges, 2 synonymous mutations and one missense mutation were detected by direct sequencing. Gene copy number analysis revealed a reduced A20 gene copy number in 8 of 45 (17.7%) patients. Furthermore, immunohistochemical staining confirmed that A20 expression correlates with the reduction of A20 gene copy number. These data suggest that A20 contributes to tumor formation in a significant fraction of myeloma patients.
Medical subject headings
- Carcinogenesis
- DNA-Binding Proteins
- Intracellular Signaling Peptides and Proteins
- Multiple Myeloma
- Nuclear Proteins
- Tumor Suppressor Proteins